clonidine hydrochloride

FDA Drug Profile — clonidine hydrochloride, Clonidine Hydrochloride, CLONIDINE HYDROCHLORIDE, Duraclon

clonidine hydrochloride is listed in the FDA National Drug Code directory with 37 NDC codes, marketed under brand names including clonidine hydrochloride, Clonidine Hydrochloride, CLONIDINE HYDROCHLORIDE. Available dosage forms: tablet, injection, solution.

Drug Details

Generic Name
clonidine hydrochloride
Brand Names
clonidine hydrochloride, Clonidine Hydrochloride, CLONIDINE HYDROCHLORIDE, Duraclon
Application Number
ANDA078895
Sponsor
A-S Medication Solutions
NDC Codes
37
Dosage Forms
TABLET, INJECTION, SOLUTION
Routes
ORAL, EPIDURAL
Active Ingredients
CLONIDINE HYDROCHLORIDE

Indications and Usage

INDICATIONS AND USAGE Clonidine hydrochloride is indicated in the treatment of hypertension. Clonidine hydrochloride may be employed alone or concomitantly with other antihypertensive agents.

Warnings

WARNINGS Withdrawal Patients should be instructed not to discontinue therapy without consulting their physician. Sudden cessation of clonidine treatment has, in some cases, resulted in symptoms such as nervousness, agitation, headache, and tremor accompanied or followed by a rapid rise in blood pressure and elevated catecholamine concentrations in the plasma. The likelihood of such reactions to discontinuation of clonidine therapy appears to be greater after administration of higher doses or continuation of concomitant beta-blocker treatment and special caution is therefore advised in these situations. Rare instances of hypertensive encephalopathy, cerebrovascular accidents and death have been reported after clonidine withdrawal. When discontinuing therapy with clonidine hydrochloride, the physician should reduce the dose gradually over 2 to 4 days to avoid withdrawal symptomatology. An excessive rise in blood pressure following discontinuation of clonidine hydrochloride therapy can be reversed by administration of oral clonidine hydrochloride or by intravenous phentolamine. If therapy is to be discontinued in patients receiving a beta-blocker and clonidine concurrently, the beta-blocker should be withdrawn several days before the gradual discontinuation of clonidine hydrochloride. Because children commonly have gastrointestinal illnesses that lead to vomiting, they may be particularly susceptible to hypertensive episodes resulting from abrupt inability to take medication.